Through its novel approach to integrate and digitally twin patient and PODular “GMP-in-a-POD” distributed manufacturing, it is rolling out across Cancer Centres of Excellence. Commencing in 2021 with its new facility in St. James’s Hospital in Dublin, this is a centre where almost 200 Bone Marrow transplant Cellular procedures take place annually.
aCGT Vector will offer Cell Therapy innovators’ accessible agile, right-sized manufacturing and clinical trial capacity across its network of POD’s. This will allow clinical trials to scale from N=1 (10-20 patient trial) to multiples of N=1 (>20 patient trials) across its multi-POD-centred clinical trials as therapies move along the clinical continuum.
Our ultimate goal is to make cancer history; by increasing accessibility to potentially curative personalised medicines, transforming lives of cancer patients, by giving consultants localised treatment options, and ultimately facilitate a paradigm shift towards distributed end-to-end point-of-care healthcare provision.
We are adapting our PODular approach to bring to market an end to end mRNA and DNA vaccine manufacturing platform using Touchlight’s dbDNA and Cytiva’s Single-use closed system FlexFactory mRNA, LNP to Vanrx fill finish technology within Ireland for broader PODular application across the EU.
